Amir H. Shojaei

Pharmacokinetics of a Guanfacine Extended‐Release Formulation in Children and Adolescents with Attention‐Deficit–Hyperactivity Disorder

A. Lyne, K. Fiske, S. Boellner, 2007, Pharmacotherapy.

A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.

A. Lyne, K. Fiske, M. Pennick, 2007, Clinical therapeutics.

LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease

Stephen C. Pflugfelder, S. Pflugfelder, M. Stern, 2017, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.

V. Perez, S. Pflugfelder, R. Haque, 2016, The ocular surface.

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

J. Hovanesian, K. Nichols, E. Donnenfeld, 2018, European journal of ophthalmology.

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).

Mitchell A Jackson, E. Holland, K. Nichols, 2017, Ophthalmology.

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial

P. Majmudar, E. Holland, K. Nichols, 2018, Clinical ophthalmology.